-
Product Insights
New![]()
Net Present Value Model: SELLAS Life Sciences Group Inc’s NeuVax
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: SELLAS Life Sciences Group Inc’s Galinpepimut-S
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CELZ-201 in Type 1 Diabetes (Juvenile Diabetes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CELZ-201 in Type 1 Diabetes (Juvenile Diabetes)Drug Details:CELZ-201 is under development for the treatment of type-1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XmAb-819 in Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.XmAb-819 in Renal Cell Carcinoma Drug Details:XmAb-30819 is under development for the treatment of renal cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DS-1055a in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DS-1055a in Metastatic Melanoma Drug Details:DS-1055a is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STP-707 in Uveal Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STP-707 in Uveal Melanoma Drug Details: STP-707 is under development for the treatment of cholangiocarcinoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Q-702 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Q-702 in Cervical Cancer Drug Details:Q-702 is under development for the treatment of advanced solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tosatoxumab in Hospital Acquired Pneumonia (HAP)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tosatoxumab in Hospital Acquired Pneumonia (HAP) Drug Details:AR-301 (KBSA301) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AROAPOC-3 in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AROAPOC-3 in Familial Chylomicronemia (Type I Hyperlipoproteinemia)Drug Details:AROAPOC-3 is under development for the treatment of hypertriglyceridemia,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200603 in Non-Small Cell Lung CancerDrug Details:HFB-200603 is under development for the treatment of solid tumor,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.